Asa Sylvia L, Baloch Zubair, Jung Chan Kwon, Cipriani Nicole A, Gamboa-Domínguez Armando, Juhlin C Christofer, Riddle Nicole D, Stojanov Ivan J, Mete Ozgur
University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.
University of Pennsylvania Medical Center - Perelman School of Medicine, Philadelphia, PA, USA.
J Pathol. 2025 Oct;267(2):130-141. doi: 10.1002/path.6456. Epub 2025 Aug 5.
The diagnostic classification of differentiated thyroid cancer has been a longstanding topic of debate among pathologists, largely due to high interobserver variability. This complexity has increased with the expansion of tumor types and subtypes. However, molecular studies have revealed a simpler and less controversial approach, categorizing these lesions into RAS-like and BRAF p.V600E-like neoplasms. In this review, the authors propose a classification that is based on, but does not require, the confirmation of molecular alterations. This approach aligns with and helps inform the pattern-based assessment of tumor growth and cytologic atypia that is already widely used in clinical practice for preoperative patient stratification and tumor diagnosis, and promises a simpler conceptual understanding. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
分化型甲状腺癌的诊断分类长期以来一直是病理学家争论的话题,主要原因是观察者之间的差异很大。随着肿瘤类型和亚型的增加,这种复杂性也在增加。然而,分子研究揭示了一种更简单且争议较小的方法,即将这些病变分为RAS样和BRAF p.V600E样肿瘤。在这篇综述中,作者提出了一种基于但不要求确认分子改变的分类方法。这种方法与临床实践中已广泛用于术前患者分层和肿瘤诊断的基于模式的肿瘤生长和细胞异型性评估相一致,并有助于为其提供信息,有望带来更简单的概念理解。© 2025作者。《病理学杂志》由约翰·威利父子有限公司代表大不列颠及爱尔兰病理学会出版。